Physician profile
Amanda E Bennett
NPI 1700302528
$1,520.51
in general payments reported to CMS, 2019-2025
18 companies · $527 in 2025
The $527 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2023: $265 · 2024: $576 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $319.69 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $237.04 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $213.34 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $114.61 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $104.59 | 2023-2024 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $96.85 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $69.87 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $60.43 | 2021 | |
| Exact Sciences Corporation | $51.80 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $48.33 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $41.77 | 2023-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Mylan Specialty L.P. | $34.98 | 2024 | Yupelri |
| Edwards Lifesciences Corporation | $27.28 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kowa Pharmaceuticals America, INC. | $25.44 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.33 | 2024 | Caplyta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.16 | 2024 | Repatha |
| Viatris Specialty LLC | $19.45 | 2025 | Yupelri |
| Phadia US INC. | $13.55 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.